Studying the effect of combination topical therapy using three medications (Dorzolamide drops, Ketorolac drops, Prednisolone drops) in treatment of Ivrin Gass syndrome (CME) post cataract surgery

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210519051344N1

Enrollment

Registered

2021-09-11

Start date

2021-06-22

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular edema after uncomplicated cataract surgery.

Interventions

Intervention group: Among the patients referred to the Charity Eye Medical Center, Tabriz University of Medical Sciences, patients who have uncomplicated cataract surgery and have CME after surgery ar

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with CME after uncomplicated cataract surgery completing informed consent form to participate in the study

Exclusion criteria

Exclusion criteria: Patients with diabetic retinopathy, retinal and vascular patients, patients with macular Patients with severe renal insufficiency, hepatic insufficiency, etc. are excluded from the study.degeneration are excluded from the study to control confounding variables. All patients admitted to the study can withdraw from the study at any time from the start of the study.

Design outcomes

Primary

Measure	Time frame
Macular thickness. Timepoint: Treatment will continue for up to 2 months after starting treatment. If CME improves before this time, the patient will be examined for up to 8 weeks. The studied variables were patient vision before starting and 2, 4, 8 weeks after starting treatment, IOP before starting and 2, 4, 8 weeks after starting treatment and macular thickness before starting treatment and 2, 4 and 8 weeks after From the beginning of treatment. Method of measurement: Oct device and Goldman tonometer.	—

Measure

Time frame

Macular thickness. Timepoint: Treatment will continue for up to 2 months after starting treatment. If CME improves before this time, the patient will be examined for up to 8 weeks. The studied variables were patient vision before starting and 2, 4, 8 weeks after starting treatment, IOP before starting and 2, 4, 8 weeks after starting treatment and macular thickness before starting treatment and 2, 4 and 8 weeks after From the beginning of treatment. Method of measurement: Oct device and Goldman tonometer.

—

Secondary

Measure	Time frame
Intraocular pressure. Timepoint: Treatment will continue for up to 2 months after starting treatment. If CME improves before this time, the patient will be examined for up to 8 weeks. The studied variables were patient vision before starting and 2, 4, 8 weeks after starting treatment, IOP before starting and 2, 4, 8 weeks after starting treatment and macular thickness before starting treatment and 2, 4 and 8 weeks after From the beginning of treatment. Method of measurement: Goldman Tonometer.	—

Measure

Time frame

Intraocular pressure. Timepoint: Treatment will continue for up to 2 months after starting treatment. If CME improves before this time, the patient will be examined for up to 8 weeks. The studied variables were patient vision before starting and 2, 4, 8 weeks after starting treatment, IOP before starting and 2, 4, 8 weeks after starting treatment and macular thickness before starting treatment and 2, 4 and 8 weeks after From the beginning of treatment. Method of measurement: Goldman Tonometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mojtaba Khalili

Tabriz University of Medical Sciences

Mojtabakhalili81@gmail.com+98 41 3657 7330

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026